ADVENZYMESAdvanced Enzyme Technologies Limited Forensic Risk Analysis

Biotechnology
Risk ClassStable
Market Cap₹3,302 Cr
Primary DriverGovernance
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
0 / 100
0 QoQ
Stable
Sentinel Insight

Financial profile remains stable for now. Pressure has stabilized in governance. This indicates that forensic pressure is currently receding. No major change in risk trend.

0.0th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹392.1▲3.31%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

No active forensic penalties contributing.
Final Composite Risk0 / 100

Investment Risk Thesis

Historical Trend

Current risk score has declined from 0 → 0 over 12 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Margin Compression
  • Inventory Stress
  • Industrial Margin Stress
What to Watch Next Quarter
  • Operating profit margins
  • Inventory turnover
  • Debt growth

Active Risk Objects (5)

CriticalHigh
Margin Compression
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumDecaying
Last SignalQ4 FY2025
Operating margin declined by 8.0 bps YoY for two consecutive quarters.

"Operating efficiency is stabilizing. The rate of margin deterioration has slowed."

Industrial Margin Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight12/15
MomentumDecaying
Last SignalQ4 FY2025
ADVENZYMES: EBITDA margin compressed by 7.8 bps YoY and Raw material costs consumed an additional 4.7% of revenue YoY.

"Operating efficiency is stabilizing. The rate of margin deterioration has slowed."

Inventory Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight15/15
MomentumDecaying
Last SignalQ2 FY2025
Inventory growth (24.2%) significantly outpaced revenue growth (-5.0%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Operating Leverage Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ1 FY2026
Expenses are consistently growing faster than revenues, creating operational pressure.

"Debt levels are creeping up. Monitor for signs of excessive borrowing for non-core activities."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumDecaying
Last SignalQ4 FY2024
Working capital expansion detected: Receivable days increased by -12.1%.

"Working capital pressure is receding. Cash previously locked in operations is being released."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)4.555.11✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+66.0+60.5✅ RESILIENT
Forensic Benchmark Context: Biotechnology (n=2 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹392.1(+3.31%)
1M Divergence+10.5%
1 Week+4.06%
1 Month+12.77%
6 Months+24.87%
1 Year+29.04%
2 Year+10.29%
3 Year+43.67%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in governance remain well-maintained against forensic benchmarks. Systematic scans of structural transparency and audit trails confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

ADVENZYMES • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.86%
Trend QualityDeveloping
Phase Progression
Phase Progression Score75%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing86%
CoinTree Momentum
Composite Z-Score+0.9397σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#262 of 2716
Top 9.65% in momentum strength
Timeframe Sparklines
1W+4.1%
1M+12.8%
6M+24.9%
Weinstein Indicators
150 DMA₹310.15
200 DMA₹313.46
150 DMA Slope+2.3991%Rising
Relative Strength+30.36%Leading
Relative Turnover (RTR)1.8047
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (5.5).
ADVENZYMESAdvanced Enzyme Technologies Limited
0 Risk
Sector %ile0th
Delta0
Active Flags5
Accel+0
Governance

Stable

ANTHEMAnthem Biosciences Limited
11 Risk
Sector %ile100th
Delta-5
Active Flags3
Accel+0
Governance

Stable

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Operating Leverage Stress

2025

Margin Compression

2025

Industrial Margin Stress

2025

Operating Leverage Stress

2025

Inventory Stress

2024

Inventory Stress

2024

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY202678117415721
FY202567013414222
FY202466113714125
FY202356610414013